nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Advances in the understanding and management of myeloproliferative disorders
|
Skoda, Radek |
|
2007 |
|
s68 |
p. 2-4 |
artikel |
2 |
Essential thrombocythaemia treatment options: addressing patient-specific needs
|
Birgegård, Gunnar |
|
2007 |
|
s68 |
p. 27-31 |
artikel |
3 |
Evolving management of essential thrombocythaemia
|
Barbui, Tiziano |
|
2007 |
|
s68 |
p. 22-23 |
artikel |
4 |
Implications of the consensus definition of clinical resistance and intolerance to hydroxyurea for clinical practice
|
Reilly, John T. |
|
2007 |
|
s68 |
p. 32-34 |
artikel |
5 |
Myelofibrosis: biology and treatment options
|
Cervantes, Francisco |
|
2007 |
|
s68 |
p. 13-17 |
artikel |
6 |
Myeloproliferative disorders: a time of new definitions Outflow from New Horizons in Haematology Meeting, 9–10 March 2007
|
Skoda, Radek |
|
2007 |
|
s68 |
p. 1 |
artikel |
7 |
New consensus: a unified definition of clinical resistance and/or intolerance to hydroxyurea in essential thrombocythaemia
|
Barosi, Giovanni |
|
2007 |
|
s68 |
p. 24-26 |
artikel |
8 |
Options in the management of essential thrombocythaemia
|
Griesshammer, Martin |
|
2007 |
|
s68 |
p. 35-39 |
artikel |
9 |
Phenotype and genotype in the myeloproliferative disorders
|
Spivak, Jerry L. |
|
2007 |
|
s68 |
p. 9-12 |
artikel |
10 |
Unanswered questions in polycythaemia vera
|
Finazzi, Guido |
|
2007 |
|
s68 |
p. 18-21 |
artikel |
11 |
Update on the impact of the JAK2 mutation on signalling pathways in myeloproliferative disorders
|
Skoda, Radek |
|
2007 |
|
s68 |
p. 5-8 |
artikel |